Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5103-5109

  Xu, Yinglei ^a   Wen, Zhengshun ^a   Xu, Zirong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiogenesis; Chitosan nanoparticles; Hepatocellular carcinoma; Necrosis; Tumor growth; VEGFR2

Indexed keywords

CHITOSAN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR NECROSIS; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHELATING AGENTS; CHITOSAN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NANOPARTICLES; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75149149835     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kew MC: Epidemiology of hepatocellular carcinoma. Toxicology 181-182: 35-38, 2002.
2. Okuda K: Hepatocellular carcinoma - history, current status and perspectives. Dig Liver Dis 34: 613-616, 2002.
3. Bergsland EK and Venook AP: Hepatocellular carcinoma. Curr Opin Oncol 12: 357-361, 2000.
4. La Vecchia C: Alcohol and liver cancer. Eur J Cancer Prev 16: 495-497, 2007.
5. Forner A, Hessheimer AJ, Isabel RM and Bruix J: Treatment of hepatocellular carcinoma. Critl Rev Oncol/Hematol 60: 89-98, 2006
6. Befeler AS and Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterol 122: 1609-1619, 2002.
7. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
8. Pralhad T, Madhusudan S and Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 55: 1045-1053, 2003.
9. Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critl Rev Oncol/Hematol 62: 179-213, 2007.
10. Shibuya M and Claesson-Welsh L: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560, 2006.
11. Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
12. Zhang HT, Craft P, Scott PA, Marina Z, Weich HA, Harris AL and Bicknell R: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87: 213-219, 1995.
13. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P and Bohlen P: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metast Rev 17: 155-161, 1998.
14. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, Greve JD, Jean-Yves D, Lathia C, Schwartz B, Taylor I, Moscovici M and Leonard BS: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
15. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140, 2008.
16. Berger J, Reist M, Chenite A, Felt-Baeyens O, Mayer JM and Gurny R: Pseudo-thermosetting chitosan hydrogels for biomedical application. Int J Pharm 288: 17-25, 2005.
17. Valérie D, and Vinod DV: Pharmaceutical applications of chitosan. Pharm Sci Tech Today 1: 246-253, 1998.
18. Sugunan A, Thanachayanont C, Dutta J and Hilborn JG: Heavy-metal ion sensors using chitosan-capped gold nanoparticles. Sci Tech of Adv Mater 6: 335-340, 2005.
19. Shahidi F, Arachchi JKV and Jeon YJ: Food applications of chitin and chitosans. Trends Food Sci Tech 10: 37-51, 1999.
20. Mailloux A, Grenet K, Bruneel A, Bénéteau B, Vaubourdolle M and Baudin B: Anticancer drugs induce necrosis of human endothelial cells involving both necrosis and apoptosis. Eur J Cell Biol 80: 442-849, 2001.
21. Janes KA, Calvo P and Alonso MJ: Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliver Rev 47: 83-97, 2001.
22. Illum L: Chitosan and its use as a pharmaceutical excipient. Pharmacol Res 15: 1326-1331, 1998.
23. Agnihotri SA, Mallikarjuna NN and Aminabhavi TM: Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Controlled Release 100: 5-28, 2004.
24. De Campos AM, Diebold Y, Carvalho EL, Sanchez A and Alonso MJ: Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharmacol Res 21: 803-810, 2004.
25. Krauland AH and Alonso MJ: Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int J Pharm 340: 134-142, 2007.
26. Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 56: 1649-1659, 2004.
27. Qi L and Xu Z: In vivo antitumor activity of chitosan nanoparticles. Bioorgan Med Chem Lett 16: 4243-4245, 2006.
28. Qi L, Xu Z, Jiang X, Li Y and Wang M: Cytotoxic activities of chitosan nanoparticles and copper-loaded nanoparticles. Bioorgan Med Chem Lett 15: 1397-1399, 2005.
29. Qi L, Xu Z, Jiang X, Hu C and Zou X: Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 339: 2693-2700, 2004.
30. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Tr 36: 169-180, 1995.
31. Friedrichs K, Gluba S, Editmann H and Jonat W: Overexpression of P53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993.
32. -ΔΔCT method. methods 25: 402-408, 2001.
33. Qi L, Xu Z and Chen M: In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. Eur J Cancer 3: 184-193, 2007.
34. Harish Prashanth KV and Tharanathan RN: Depolymerized products of chitosan as potent inhibitors of tumor-induced angiogenesis. Biochim Biophys Acta 1722: 22-29, 2005.